Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company specializing in the discovery, research, and development of next-generation biologic drugs and novel oncology therapeutics. The company's proprietary drug development platforms include PolyXen™, which enhances the half-life and other pharmacological properties of biologic drugs.
Xenetic’s lead investigational product candidates comprise the FDA orphan-designated oncology therapeutic Sodium Cridanimod for progesterone receptor-negative endometrial cancer, and a polysialylated form of erythropoietin for treating anemia in pre-dialysis patients with chronic kidney disease. Xenetic is also collaborating with Shire PLC (formerly Baxalta, Baxter Incorporated, and Baxter Healthcare) to develop polysialylated blood coagulation factors, including a next-generation Factor VIII.
In the immune-oncology space, Xenetic is advancing XCART, a personalized CAR T platform technology, and the DNase platform aimed at improving existing treatments by targeting neutrophil extracellular traps (NETs) implicated in cancer progression and resistance. The company is working towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors.
Recent financial updates reveal that Xenetic ended Q2 2023 with approximately $10.7 million in cash and no debt. The company reported a net loss of $1.1 million for Q3 2023 and continued to secure strategic collaborations and advance its DNase-based oncology program.
Xenetic Biosciences (NASDAQ: XBIO) has announced a significant collaboration with The Scripps Research Institute to advance its systemic DNase-based oncology program, aimed at treating pancreatic carcinoma and other solid tumors. This partnership will enhance the development of the DNase platform, which targets neutrophil extracellular traps (NETs), implicated in cancer progression and therapeutic resistance. Xenetic plans to initiate a first-in-human study assessing the DNase in combination with immune checkpoint inhibitors or chemotherapy. Furthermore, the agreement allows Xenetic to acquire an exclusive license for any new intellectual property resulting from the research. This collaboration is seen as a critical step towards creating much-needed therapies for challenging cancer indications.
Xenetic Biosciences (NASDAQ: XBIO) reported significant developments in its annual results for 2022. The company is focusing on the DNase oncology platform, which targets neutrophil extracellular traps to improve cancer therapies. The DNase program is progressing towards Phase 1 clinical development and aims to provide treatments for pancreatic carcinoma and other solid tumors. The year ended with approximately $13.1 million in cash. Financially, the net loss for 2022 was $6.6 million, with a 50.8% increase in research and development expenses. A royalty payment of $1.7 million was received from a sublicense with Takeda, marking a 47.1% year-over-year increase.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced participation in the Virtual Investor NETs in Cancer Spotlight Event on March 29, 2023, at 11:00 AM ET. CEO Jeffrey Eisenberg, CSO Curtis Lockshin, and oncology leader Dr. Jonathan Spicer will discuss the Company's DNase-based oncology platform and the role of Neutrophil Extracellular Traps (NETs) in cancer. The event will feature a moderated roundtable discussion, enabling investors to submit questions live. A live video webcast will be available on Xenetic's website and archived for 90 days.
Xenetic Biosciences (NASDAQ: XBIO) announced that the Canadian Intellectual Property Office has issued a notice of allowance for Patent Application No. 3,001,543, titled Method to Improve Safety and Efficacy of Anti-Cancer Therapy. This patent application aims to improve treatments for cancer patients by using a DNase enzyme to mitigate chemotherapy-associated side effects. CEO Jeffrey Eisenberg emphasized the company's commitment to advancing its DNase platform and strengthening its intellectual property portfolio. The approved patent enhances Xenetic's capabilities in the oncology sector, specifically targeting pancreatic carcinoma and other difficult-to-treat cancers.
Xenetic Biosciences (NASDAQ: XBIO) will present at the Virtual Investor 2023 Companies to Watch Event on January 17, 2023, at 10:00 AM ET. CEO Jeffrey Eisenberg will showcase the company's advancements in immune-oncology technologies aimed at treating hard-to-treat cancers. A live video webcast will be available on the company's Investors website page, with a replay accessible for 90 days post-event. Xenetic specializes in DNase platforms for cancer treatment and the XCART™ technology for personalized CAR T therapies.
FAQ
What is the current stock price of Xenetic Biosciences (XBIO)?
What is the market cap of Xenetic Biosciences (XBIO)?
What is Xenetic Biosciences' main focus?
What are the primary platforms used by Xenetic Biosciences?
What are Xenetic Biosciences' lead investigational products?
Who are Xenetic Biosciences' key partners?
What is the focus of Xenetic's DNase platform?
What are the company's recent financial highlights?
What is the goal of Xenetic's XCART technology?
What are the company’s plans for its DNase-based oncology program?
How does the PolyXen™ platform benefit biologic drugs?
Where can I find more information about Xenetic Biosciences?
